BioSpace News Archive

AbbVie (NYSE: ABBV) will present further analyses on SKYRIZI® (risankizumab) in Crohn’s disease (CD) and RINVOQ® (upadacitinib) in ulcerative colitis (UC) as well as the investigational use of upadacitinib in CD at the 18th Congress of European Crohn’s and Colitis Organisation (ECCO), to be held March 1-4 in Copenhagen, Denmark.

InDex Pharmaceuticals Holding AB (publ) today announced that the company will attend the annual congress of the European Crohn’s and Colitis Organisation (ECCO), March 1-4, 2023 in Copenhagen.

SpringWorks Therapeutics, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) for nirogacestat.

BIOLASE, Inc. has launched a new e-commerce website for its U.S. customers.

Protalix BioTherapeutics, Inc. today reported financial results for the fiscal year ended December 31, 2022 and provided a business update on recent corporate and regulatory developments.

Asensus Surgical, Inc. announced today that it plans to release fourth quarter and full year 2022 financial and operating results after the market closes on Thursday, March 2, 2023.

Bright Minds Biosciences Inc. today provided an update on its clinical programs, anticipated upcoming milestones and strategic priorities for advancing its development pipeline of innovative treatments to heal the central nervous system (CNS) and brain through the regulation of serotonin.

Passage Bio, Inc. today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, March 6, 2023 to report its fourth quarter and full-year 2022 financial results and discuss recent business highlights.

Entrada Therapeutics, Inc. today announced that Dipal Doshi, President and Chief Executive Officer, will participate on the Neuromuscular and Bone Corporate Panel at the Cowen 43rd Annual Health Care Conference.

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, and Rallybio Corporation, a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced a research collaboration.